NCT06522035

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Enlivex Therapeutics Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open label study to evaluate the safety and initial efficacy of intra-articular administration of Allocetra in patients with Psoriatic Arthritis (PsA).

Detailed description

Psoriatic Arthritis (PsA) is a prevalent chronic inflammatory disease that mainly affects the synovial joints, and leads to inflammatory arthritis, in addition to skin manifestations. If left untreated, inflammatory arthritis leads to joint damage and deformities. Allocetra is an immunomodulatory cell-based therapy consisting of allogeneic peripheral blood mononuclear cells that have been modified to be engulfed by macrophages and reprogram them into their homeostatic state. As macrophages play a crucial role in the initiation of PsA immunopathogenesis, they are considered an emerging target for PsA treatment. This study will assess the safety of Allocetra injection to the joint (knee, elbow or ankle) in patients with PsA, and evaluate the preliminary responses to treatment.

Conditions

• Arthritis, Psoriatic

Interventions

Type	Name	Description
DRUG	Allocetra	Intra-articular injecton of Allocetra into the target joint.

Timeline

• Start date: 2024-08-01
• Primary completion: 2025-10-20
• Completion: 2026-04-08
• First posted: 2024-07-26
• Last updated: 2026-04-13

Locations

4 sites across 1 country: Israel